Repligen Balance Sheet
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Repligen financial position
At the end of fiscal 2025, Repligen reported total assets of $2.95 billion, up 4.2% from a year earlier against total liabilities of $843.6 million. Shareholders' equity stood at $2.11 billion, or 71.4% of assets. The company held $566.0 million in cash and equivalents against $542.2 million of debt, a net cash position of $23.8 million.
The current ratio (current assets divided by current liabilities) was 8.37, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.26.
Summary generated from market data by MetaCap's automated system. Methodology
Repligen balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 566.02M | 757.36M | 751.32M | 523.46M | 603.81M | 717.29M | 528.39M | 193.82M | 173.76M | 122.23M |
| Short-Term Investments | 201.61M | 0 | — | — | — | — | — | 0 | 0 | 19.55M |
| Receivables | 158.59M | 134.12M | 124.16M | 116.25M | 117.42M | 71.39M | 43.07M | 33.02M | 27.59M | 15.19M |
| Inventory | 170.46M | 142.96M | 202.32M | 238.28M | 184.49M | 95.03M | 54.83M | 42.26M | 39.00M | 24.70M |
| Total Current Assets | 1.14B | 1.07B | 1.11B | 998.12M | 931.68M | 902.38M | 641.83M | 275.74M | 242.78M | 184.15M |
| Property, Plant & Equipment | 186.61M | 197.74M | 207.44M | 190.67M | 124.96M | 66.87M | 48.45M | 32.18M | 22.42M | 14.96M |
| Goodwill | 1.11B | 1.03B | 987.12M | 855.51M | 860.36M | 618.30M | 468.41M | 326.74M | 327.33M | 59.55M |
| Intangible Assets | 386.15M | 397.90M | 406.96M | 360.62M | 337.27M | 287.10M | 212.55M | 135.44M | 144.75M | 29.81M |
| Long-Term Investments | — | — | — | — | — | — | — | — | — | 0 |
| Total Assets | 2.95B | 2.83B | 2.83B | 2.53B | 2.36B | 1.90B | 1.40B | 774.62M | 743.52M | 288.91M |
| Accounts Payable | 30.01M | 32.13M | 19.56M | 27.55M | 36.20M | 16.88M | 11.43M | 10.49M | 7.28M | 5.06M |
| Total Current Liabilities | 135.83M | 126.79M | 164.94M | 404.20M | 375.26M | 318.96M | 48.31M | 129.84M | 25.21M | 21.07M |
| Long-Term Debt | 542.21M | 525.57M | — | — | — | — | — | — | — | — |
| Total Liabilities | 843.57M | 856.95M | 866.34M | 620.90M | 608.29M | 373.74M | 340.35M | 159.05M | 151.97M | 120.15M |
| Shareholders' Equity | 2.11B | 1.97B | 1.96B | 1.91B | 1.75B | 1.53B | 1.06B | 615.57M | 591.55M | 168.76M |
| Retained Earnings | 456.25M | 407.35M | 432.87M | 397.27M | 194.06M | 65.77M | 5.84M | -677.00K | -31.51M | -59.86M |
| Total Debt | 542.21M | 525.57M | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 225.41M | 231.79M | 751.32M | 523.46M | 603.81M | 717.29M | 528.39M | 193.82M | 173.76M | 141.78M |
| Shares Outstanding | 56.33M | 56.09M | 55.77M | 55.56M | 55.32M | 54.76M | 52.08M | 43.92M | 43.59M | 33.84M |
This table shows 10 annual periods of Repligen's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RGEN's reporting calendar. What is a balance sheet?